DB:M6X2

Stock Analysis Report

Executive Summary

Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for step-changing improvements in crop yield in the United States and Canada.

Rewards

Earnings are forecast to grow 38.82% per year

Earnings have grown 25.3% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($801K)

Does not have a meaningful market cap (€6M)

Highly volatile share price over past 3 months

+ 2 more risks


Snowflake Analysis

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Yield10 Bioscience's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: M6X2's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.1%

M6X2

0.4%

DE Biotechs

0.2%

DE Market


1 Year Return

-82.1%

M6X2

9.0%

DE Biotechs

14.4%

DE Market

Return vs Industry: M6X2 underperformed the German Biotechs industry which returned 7.2% over the past year.

Return vs Market: M6X2 underperformed the German Market which returned 14.1% over the past year.


Shareholder returns

M6X2IndustryMarket
7 Day5.1%0.4%0.2%
30 Day19.2%-2.1%0.9%
90 Day772.0%8.0%4.6%
1 Year-82.1%-82.1%9.2%9.0%17.9%14.4%
3 Year-94.3%-94.3%45.5%43.9%15.7%5.6%
5 Year-99.4%-99.4%12.8%10.5%23.4%6.5%

Price Volatility Vs. Market

How volatile is Yield10 Bioscience's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Yield10 Bioscience undervalued compared to its fair value and its price relative to the market?

0.93x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate M6X2's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate M6X2's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: M6X2 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: M6X2 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate M6X2's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: M6X2 is good value based on its PB Ratio (0.9x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Yield10 Bioscience forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

38.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: M6X2 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: M6X2 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: M6X2's is expected to become profitable in the next 3 years.

Revenue vs Market: M6X2's revenue (67.4% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: M6X2's revenue (67.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if M6X2's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Yield10 Bioscience performed over the past 5 years?

25.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: M6X2 is currently unprofitable.

Growing Profit Margin: M6X2 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: M6X2 is unprofitable, but has reduced losses over the past 5 years at a rate of 25.3% per year.

Accelerating Growth: Unable to compare M6X2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: M6X2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: M6X2 has a negative Return on Equity (-303.82%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Yield10 Bioscience's financial position?


Financial Position Analysis

Short Term Liabilities: M6X2's short term assets ($3.5M) exceed its short term liabilities ($1.8M).

Long Term Liabilities: M6X2's short term assets ($3.5M) do not cover its long term liabilities ($5.0M).


Debt to Equity History and Analysis

Debt Level: M6X2 is debt free.

Reducing Debt: M6X2 has not had any debt for past 5 years.


Balance Sheet

Inventory Level: M6X2 has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if M6X2's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: M6X2 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: M6X2 has less than a year of cash runway if free cash flow continues to grow at historical rates of 24.1% each year.


Next Steps

Dividend

What is Yield10 Bioscience's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate M6X2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate M6X2's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if M6X2's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if M6X2's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of M6X2's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Olly Peoples (61yo)

3.3yrs

Tenure

US$738,252

Compensation

Dr. Oliver P. Peoples, also known as Olly, Ph.D., is a Co-founder of Metabolix Inc., and has been its Chief Executive Officer and President since October 17, 2016. Dr. Peoples served as its Chief Scientifi ...


CEO Compensation Analysis

Compensation vs Market: Olly's total compensation ($USD738.25K) is above average for companies of similar size in the German market ($USD413.42K).

Compensation vs Earnings: Olly's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Oliver Peoples
Co-Founder3.3yrsUS$738.25k0.35% $19.9k
Anthony Sinskey
Co-Founder & Director27.7yrsUS$60.96k0.040% $2.2k
Kristi Snell
VP of Research & Chief Science Officer3.3yrsUS$467.78k0.14% $7.9k
Lynne Brum
VP of Planning & Corporate Communications and Secretary3.3yrsUS$372.11k0.15% $8.6k
Charles Haaser
VP of Finance3.3yrsUS$251.94k0.13% $7.2k

3.3yrs

Average Tenure

61yo

Average Age

Experienced Management: M6X2's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Oliver Peoples
Co-Founder3.3yrsUS$738.25k0.35% $19.9k
Anthony Sinskey
Co-Founder & Director27.7yrsUS$60.96k0.040% $2.2k
Richard Hamilton
Independent Director2.9yrsUS$65.96k0.0097% $548.5
Joseph Shaulson
Independent Director6.2yrsUS$43.46k0.11% $6.4k
Robert Van Nostrand
Independent Chairman of the Board6.3yrsUS$85.96k0.036% $2.0k
Edward Muller
Chairman Emeritus0yrsUS$83.81kno data
Heike Sederoff
Member of Scientific Advisory Board3.4yrsno datano data
Danny Schnell
Member of Scientific Advisory Board4yrsno datano data
Jay Thelen
Member of Scientific Advisory Board1.6yrsno datano data
Sherri Brown
Director0yrsno datano data

5.1yrs

Average Tenure

61.5yo

Average Age

Experienced Board: M6X2's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: M6X2 insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35%.


Top Shareholders

Company Information

Yield10 Bioscience, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Yield10 Bioscience, Inc.
  • Ticker: M6X2
  • Exchange: DB
  • Founded: 1992
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$6.090m
  • Listing Market Cap: US$5.643m
  • Shares outstanding: 781.81k
  • Website: https://www.yield10bio.com

Number of Employees


Location

  • Yield10 Bioscience, Inc.
  • 19 Presidential Way
  • Woburn
  • Massachusetts
  • 1801
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
YTENNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2006
M6X2DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2006

Biography

Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for step-changing improvements in crop yield in the United States and Canada. The company, through its Trait Factory, is involved in developing high value seed traits for the agriculture and food industries. It also has an oilseed development center in Saskatchewan, Canada. Yield10 Bioscience, Inc. has a research agreement with J. R. Simplot Company to evaluate three novel yield traits in potato. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was founded in 1992 and is headquartered in Woburn, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 21:19
End of Day Share Price2020/02/20 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.